Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment.

Citation

• Clingan, P. R., Ackland, S. P., Ranson, M., Brungs, D., Aghmesheh, M., Tafreshi, A., . . . De Souza, P. L. (2017). Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment.. Journal of Clinical Oncology, 35(15_suppl), 2529. doi:10.1200/jco.2017.35.15_suppl.2529

Digital Object Identifier (doi)

• 10.1200/jco.2017.35.15_suppl.2529

Web Of Science Accession Number

Start Page

• 2529

End Page

• 2529

Volume

• 35

Issue

• 15_suppl

Abstract

UOW Authors

•   Aghmesheh, Morteza (external author)
•   Brungs, Daniel
•   Clingan, Phillip (external author)
•   De Souza, Paul (external author)
•   Ranson, Marie

Publication Date

• 2017

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Clingan, P. R., Ackland, S. P., Ranson, M., Brungs, D., Aghmesheh, M., Tafreshi, A., . . . De Souza, P. L. (2017). Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment.. Journal of Clinical Oncology, 35(15_suppl), 2529. doi:10.1200/jco.2017.35.15_suppl.2529

Digital Object Identifier (doi)

• 10.1200/jco.2017.35.15_suppl.2529

Web Of Science Accession Number

Start Page

• 2529

End Page

• 2529

Volume

• 35

Issue

• 15_suppl